LIDE Biotech supports translational oncology programs with patient-derived xenograft models, organoids, primary tumor cells, and clinically annotated biospecimens. Its platforms cover a broad range of cancer types and are used for efficacy studies, biomarker exploration, combination testing, and patient-selection research. By linking preclinical models with molecular and clinical information, LIDE helps sponsors evaluate how therapies may perform across diverse tumor populations.
Shanghai LIDE Biotech Co., Ltd. (LIDE Biotech)
LIDE Biotech is committed to engaging in translational medicine and precision medical research to help guide clinical research and optimize therapeutics for patients around the world, expanding the availability of precision treatment options.
